Resmed Inc (RMD) 67.36 $RMD New Study Shows Usi
Post# of 273322
Posted On: 09/06/2016 3:11:52 PM
Resmed Inc (RMD) 67.36 $RMD
New Study Shows Using Non-Invasive Ventilation Therapy to Treat Patients with Chronic Obstructive Pulmonary Disorder (COPD) at Home Significantly Reduces Risk of Re-Hospitalization and Death
PR Newswire - Tue Sep 06, 7:51AM CDT
ResMed (NYSE: RMD) welcomed positive results from a multicenter, randomized controlled trial known as HOT-HMV. The study was presented today during the 2016 European Respiratory Society International Congress, in London.
RMD: 67.36 (+0.30)
ResMed Expands COPD Offering as New Data Reveals Benefits of Home Non-Invasive Ventilation
BusinessWire - Tue Sep 06, 12:00AM CDT
--ResMed at-home COPD management portfolio now includes portable oxygen therapy, alongside home NIV and remote monitoring technology
RMD: 67.36 (+0.30)
Herbalife, Wells Fargo gain; Caesars Entertainment sinks
AP - Mon Aug 29, 3:49PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
INO: 8.93 (-0.15), HLF: 62.29 (+0.94), CF: 25.68 (-0.26), RMD: 67.36 (+0.30), USG: 27.17 (-0.39), WFC: 49.89 (-0.66), CZR: 6.17 (+0.02)
Look for Shares of ResMed to Potentially Rebound after Yesterday's 1.52% Sell Off
Comtex SmarTrend(R) - Mon Aug 29, 1:14PM CDT
ResMed (NYSE:RMD) traded in a range yesterday that spanned from a low of $65.65 to a high of $68.19. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $67.32 on volume of 840,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
RMD: 67.36 (+0.30)
Downgrade Alert for ResMed (RMD)
Comtex SmarTrend(R) - Wed Aug 24, 3:13AM CDT
ResMed (NYSE:RMD) was downgraded from Hold to Underperform at Jefferies today. The stock closed yesterday at $67.32 on volume of 3.0 million shares, above average daily volume of 1.1 million. ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing. The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors.
RMD: 67.36 (+0.30)
ResMed Falls 1.88% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 23, 12:35PM CDT
ResMed (NYSE:RMD) traded in a range yesterday that spanned from a low of $67.56 to a high of $68.92. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $68.57 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
RMD: 67.36 (+0.30)
ResMed Takes Fisher & Paykel to Court over Patents
PR Newswire Europe - Wed Aug 17, 4:18PM CDT
- ResMed files patent infringement actions against Fisher & Paykel Healthcare in U.S., German and New Zealand courts and in the U.S. International Trade Commission
RMD: 67.36 (+0.30)
ResMed Set to Possibly Pullback After Yesterday's Rally of 4.90%
Comtex SmarTrend(R) - Fri Jul 29, 2:18PM CDT
ResMed (NYSE:RMD) traded in a range yesterday that spanned from a low of $68.29 to a high of $69.38. Yesterday, the shares gained 4.9%, which took the trading range above the 3-day high of $65.98 on volume of 998,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
RMD: 67.36 (+0.30)
ResMed (RMD) Q4 Earnings in Line, Revenues Top Estimates
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:14AM CDT
ResMed ended fiscal 2016 on a modest note, with fourth-quarter revenues beating estimates and earnings meeting the same.
BABY: 41.90 (+1.26), ABMD: 117.84 (+0.41), MASI: 59.31 (-0.59), RMD: 67.36 (+0.30)
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2016
PR Newswire - Thu Jul 28, 3:05PM CDT
ResMed Inc. (NYSE: RMD) today announced results for its quarter ended June 30, 2016. Revenue for the quarter was $518.6 million, a 14 percent increase compared to the same period of the prior year, or a 15 percent increase on a constant currency basis. Excluding the contribution from the Brightree acquisition, revenue for the quarter was $489.7 million, an 8 percent increase.
RMD: 67.36 (+0.30)
Watch for ResMed to Potentially Pullback After Gaining 3.15% Yesterday
Comtex SmarTrend(R) - Tue Jun 21, 3:19PM CDT
ResMed (NYSE:RMD) traded in a range yesterday that spanned from a low of $60.32 to a high of $61.74. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $59.92 on volume of 655,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
RMD: 67.36 (+0.30)
ResMed Statement on Brightree Executive Appointments
PR Newswire - Mon Jun 20, 8:00AM CDT
ResMed (NYSE:RMD) today issued the following statement related to Brightree's announcement of its new executive team, from president of healthcare informatics Raj Sodhi:
RMD: 67.36 (+0.30)
Kaiser Permanente Study: ResMed Digital Platform Drives CPAP Adherence
PR Newswire - Mon Jun 13, 8:00AM CDT
Remote monitoring and automated coaching from ResMed (NYSE: RMD) significantly improve the use of continuous positive airway pressure therapy for patients with obstructive sleep apnea, according to an independent Kaiser Permanente study presented last night at the SLEEP conference in Denver - the largest-ever randomized, controlled study on OSA in the United States.
RMD: 67.36 (+0.30)
Technical Pulse on Medical Appliances & Equipment Stocks -- St. Jude Medical, ResMed, Steris, and Varian Medical Systems
PR Newswire - Mon Jun 06, 8:00AM CDT
On Friday, June 03, 2016, the NASDAQ Composite ended the trading session at 4,942.52, down 0.58%; the Dow Jones Industrial Average lost 0.18% to finish at 17,807.06; and the S&P 500 closed at 2,099.13, down 0.29%. ActiveWallSt.com has initiated coverage on the following equities: St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), Steris PLC (NYSE: STE), and Varian Medical Systems Inc. (NYSE: VAR). Learn more about these stocks by accessing their free trade alerts at:
VAR: 96.26 (-0.15), STE: 71.30 (+0.30), RMD: 67.36 (+0.30), STJ: 78.91 (+0.26), MDSY: 1.30 (-0.08)
ResMed Posts Mixed Q3 Results, Brightree Buyout on Track
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:35AM CDT
ResMed (RMD) posted a lackluster third-quarter fiscal 2016. Nevertheless, ResMed's segmental as well as geographical performance was strong.
BSX: 24.30 (+0.04), SRDX: 28.59 (-0.89), BAX: 45.90 (-0.38), RMD: 67.36 (+0.30)
ResMed: Positive CAT-HF Study Results to Drive ASV Sales
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:51AM CDT
The positive CAT-HF study results encourage us to expect a rise in demand for the wide range of products offered by ResMed (RMD) in the respiratory care market.
BSX: 24.29 (+0.03), SRDX: 28.59 (-0.89), BAX: 45.90 (-0.38), RMD: 67.36 (+0.30)
Adaptive Servo-ventilation (ASV) Therapy Suggests Positive Cardiovascular Outcomes for People with Sleep-Disordered Breathing and Heart Failure With Preserved Ejection Fraction In Phase II Study
PR Newswire - Sun May 22, 1:40AM CDT
FLORENCE, Italy, May 22, 2016 /PRNewswire/-- ResMed (NYSE: RMD) today announced primary results from a multicenter, randomized controlled Phase II trial known as CAT-HF presented at the European Society of Cardiology's 2016 Annual Heart Failure Congress. CAT-HF assessed whether the treatment of moderate to severe sleep-disordered breathing (obstructive or central sleep apnea) with adaptive servo-ventilation (ASV) therapy could improve cardiovascular outcomes in patients who were hospitalized for a sudden worsening of their heart failure symptoms (acute decompensated heart failure) over six months.
RMD: 67.36 (+0.30)
ResMed Life Support Ventilators to Join World's Largest Remote Patient Monitoring Network
PR Newswire - Mon May 16, 5:30AM CDT
Patients using in-home life support and their clinicians are about to enjoy the latest in home health technology, remote patient monitoring, thanks to the world's first cellular, cloud-connected in-home life support ventilators.
RMD: 67.36 (+0.30)
International Trade Commission to Investigate Chinese Manufacturer BMC Medical's Infringement of ResMed Patents
PR Newswire - Fri May 13, 5:00AM CDT
ResMed (NYSE:RMD) the world's leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care, announced today that the United States International Trade Commission (ITC) has accepted its request to investigate alleged infringement of its patented technology by Chinese medical device manufacturer BMC Medical Co., Ltd. and its U.S. distributor, 3B Medical.
RMD: 67.36 (+0.30)
New Study Shows Using Non-Invasive Ventilation Therapy to Treat Patients with Chronic Obstructive Pulmonary Disorder (COPD) at Home Significantly Reduces Risk of Re-Hospitalization and Death
PR Newswire - Tue Sep 06, 7:51AM CDT
ResMed (NYSE: RMD) welcomed positive results from a multicenter, randomized controlled trial known as HOT-HMV. The study was presented today during the 2016 European Respiratory Society International Congress, in London.
RMD: 67.36 (+0.30)
ResMed Expands COPD Offering as New Data Reveals Benefits of Home Non-Invasive Ventilation
BusinessWire - Tue Sep 06, 12:00AM CDT
--ResMed at-home COPD management portfolio now includes portable oxygen therapy, alongside home NIV and remote monitoring technology
RMD: 67.36 (+0.30)
Herbalife, Wells Fargo gain; Caesars Entertainment sinks
AP - Mon Aug 29, 3:49PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
INO: 8.93 (-0.15), HLF: 62.29 (+0.94), CF: 25.68 (-0.26), RMD: 67.36 (+0.30), USG: 27.17 (-0.39), WFC: 49.89 (-0.66), CZR: 6.17 (+0.02)
Look for Shares of ResMed to Potentially Rebound after Yesterday's 1.52% Sell Off
Comtex SmarTrend(R) - Mon Aug 29, 1:14PM CDT
ResMed (NYSE:RMD) traded in a range yesterday that spanned from a low of $65.65 to a high of $68.19. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $67.32 on volume of 840,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
RMD: 67.36 (+0.30)
Downgrade Alert for ResMed (RMD)
Comtex SmarTrend(R) - Wed Aug 24, 3:13AM CDT
ResMed (NYSE:RMD) was downgraded from Hold to Underperform at Jefferies today. The stock closed yesterday at $67.32 on volume of 3.0 million shares, above average daily volume of 1.1 million. ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing. The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors.
RMD: 67.36 (+0.30)
ResMed Falls 1.88% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 23, 12:35PM CDT
ResMed (NYSE:RMD) traded in a range yesterday that spanned from a low of $67.56 to a high of $68.92. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $68.57 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
RMD: 67.36 (+0.30)
ResMed Takes Fisher & Paykel to Court over Patents
PR Newswire Europe - Wed Aug 17, 4:18PM CDT
- ResMed files patent infringement actions against Fisher & Paykel Healthcare in U.S., German and New Zealand courts and in the U.S. International Trade Commission
RMD: 67.36 (+0.30)
ResMed Set to Possibly Pullback After Yesterday's Rally of 4.90%
Comtex SmarTrend(R) - Fri Jul 29, 2:18PM CDT
ResMed (NYSE:RMD) traded in a range yesterday that spanned from a low of $68.29 to a high of $69.38. Yesterday, the shares gained 4.9%, which took the trading range above the 3-day high of $65.98 on volume of 998,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
RMD: 67.36 (+0.30)
ResMed (RMD) Q4 Earnings in Line, Revenues Top Estimates
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:14AM CDT
ResMed ended fiscal 2016 on a modest note, with fourth-quarter revenues beating estimates and earnings meeting the same.
BABY: 41.90 (+1.26), ABMD: 117.84 (+0.41), MASI: 59.31 (-0.59), RMD: 67.36 (+0.30)
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2016
PR Newswire - Thu Jul 28, 3:05PM CDT
ResMed Inc. (NYSE: RMD) today announced results for its quarter ended June 30, 2016. Revenue for the quarter was $518.6 million, a 14 percent increase compared to the same period of the prior year, or a 15 percent increase on a constant currency basis. Excluding the contribution from the Brightree acquisition, revenue for the quarter was $489.7 million, an 8 percent increase.
RMD: 67.36 (+0.30)
Watch for ResMed to Potentially Pullback After Gaining 3.15% Yesterday
Comtex SmarTrend(R) - Tue Jun 21, 3:19PM CDT
ResMed (NYSE:RMD) traded in a range yesterday that spanned from a low of $60.32 to a high of $61.74. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $59.92 on volume of 655,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
RMD: 67.36 (+0.30)
ResMed Statement on Brightree Executive Appointments
PR Newswire - Mon Jun 20, 8:00AM CDT
ResMed (NYSE:RMD) today issued the following statement related to Brightree's announcement of its new executive team, from president of healthcare informatics Raj Sodhi:
RMD: 67.36 (+0.30)
Kaiser Permanente Study: ResMed Digital Platform Drives CPAP Adherence
PR Newswire - Mon Jun 13, 8:00AM CDT
Remote monitoring and automated coaching from ResMed (NYSE: RMD) significantly improve the use of continuous positive airway pressure therapy for patients with obstructive sleep apnea, according to an independent Kaiser Permanente study presented last night at the SLEEP conference in Denver - the largest-ever randomized, controlled study on OSA in the United States.
RMD: 67.36 (+0.30)
Technical Pulse on Medical Appliances & Equipment Stocks -- St. Jude Medical, ResMed, Steris, and Varian Medical Systems
PR Newswire - Mon Jun 06, 8:00AM CDT
On Friday, June 03, 2016, the NASDAQ Composite ended the trading session at 4,942.52, down 0.58%; the Dow Jones Industrial Average lost 0.18% to finish at 17,807.06; and the S&P 500 closed at 2,099.13, down 0.29%. ActiveWallSt.com has initiated coverage on the following equities: St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), Steris PLC (NYSE: STE), and Varian Medical Systems Inc. (NYSE: VAR). Learn more about these stocks by accessing their free trade alerts at:
VAR: 96.26 (-0.15), STE: 71.30 (+0.30), RMD: 67.36 (+0.30), STJ: 78.91 (+0.26), MDSY: 1.30 (-0.08)
ResMed Posts Mixed Q3 Results, Brightree Buyout on Track
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:35AM CDT
ResMed (RMD) posted a lackluster third-quarter fiscal 2016. Nevertheless, ResMed's segmental as well as geographical performance was strong.
BSX: 24.30 (+0.04), SRDX: 28.59 (-0.89), BAX: 45.90 (-0.38), RMD: 67.36 (+0.30)
ResMed: Positive CAT-HF Study Results to Drive ASV Sales
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:51AM CDT
The positive CAT-HF study results encourage us to expect a rise in demand for the wide range of products offered by ResMed (RMD) in the respiratory care market.
BSX: 24.29 (+0.03), SRDX: 28.59 (-0.89), BAX: 45.90 (-0.38), RMD: 67.36 (+0.30)
Adaptive Servo-ventilation (ASV) Therapy Suggests Positive Cardiovascular Outcomes for People with Sleep-Disordered Breathing and Heart Failure With Preserved Ejection Fraction In Phase II Study
PR Newswire - Sun May 22, 1:40AM CDT
FLORENCE, Italy, May 22, 2016 /PRNewswire/-- ResMed (NYSE: RMD) today announced primary results from a multicenter, randomized controlled Phase II trial known as CAT-HF presented at the European Society of Cardiology's 2016 Annual Heart Failure Congress. CAT-HF assessed whether the treatment of moderate to severe sleep-disordered breathing (obstructive or central sleep apnea) with adaptive servo-ventilation (ASV) therapy could improve cardiovascular outcomes in patients who were hospitalized for a sudden worsening of their heart failure symptoms (acute decompensated heart failure) over six months.
RMD: 67.36 (+0.30)
ResMed Life Support Ventilators to Join World's Largest Remote Patient Monitoring Network
PR Newswire - Mon May 16, 5:30AM CDT
Patients using in-home life support and their clinicians are about to enjoy the latest in home health technology, remote patient monitoring, thanks to the world's first cellular, cloud-connected in-home life support ventilators.
RMD: 67.36 (+0.30)
International Trade Commission to Investigate Chinese Manufacturer BMC Medical's Infringement of ResMed Patents
PR Newswire - Fri May 13, 5:00AM CDT
ResMed (NYSE:RMD) the world's leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care, announced today that the United States International Trade Commission (ITC) has accepted its request to investigate alleged infringement of its patented technology by Chinese medical device manufacturer BMC Medical Co., Ltd. and its U.S. distributor, 3B Medical.
RMD: 67.36 (+0.30)
(0)
(0)